Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Pediatric Transplants

Pediatric standard-risk AML with fully matched sibling donors: to transplant in first CR or not?

Bone Marrow Transplantation volume 42, pages 393–396 (2008)Cite this article

Abstract

Allogeneic hematopoietic SCT (HSCT) for children with standard-risk AML in first CR (CR1) is controversial. We reviewed 32 consecutive children with standard-risk AML who received matched sibling donor HSCT in CR1 from 1995 to 2004. With a median follow-up of 76 months (range: 36–114), 3 year EFS was 0.74 (95% confidence interval (CI): 0.57–0.88) and the overall survival was 0.81 (95% CI: 0.66–0.93). Only one patient died as a result of TRM. Larger studies, such as the MRC-UK 10 and 12, reported 60–62% EFS. Outcome of children with standard-risk AML transplanted from a matched sibling donor in CR1 is very encouraging with minimal toxicity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Arceci RJ . Progress and controversies in the treatment of pediatric acute myelogenous leukemia. Curr Opin Hematol 2002; 9: 353–360.

    Article  PubMed  Google Scholar 

  2. Gibson BE, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK . Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 19: 2130–2138.

    Article  CAS  PubMed  Google Scholar 

  3. Frassoni F, Labopin M, Gluckman E, Prentice HG, Vernant JP, Zwaan F et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time—a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplant 1996; 17: 13–18.

    CAS  PubMed  Google Scholar 

  4. Michel G, Leverger G, Leblanc T, Nelken B, Baruchel A, Landman-Parker J et al. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Bone Marrow Transplant 1996; 17: 191–196.

    CAS  PubMed  Google Scholar 

  5. Neudorf S, Sanders J, Kobrinsky N, Alonzo TA, Buxton AB, Gold S et al. Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood 2004; 103: 3655–3661.

    Article  CAS  PubMed  Google Scholar 

  6. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 832–843, 895–902.

    Article  CAS  PubMed  Google Scholar 

  7. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H et al. A controlled trial of fluconazole to prevent infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845–851.

    Article  CAS  PubMed  Google Scholar 

  8. Goodrich JM, Bowden RA, Fisher L, Keller C, Meyers JD . Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 18: 173–178.

    Article  Google Scholar 

  9. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA . Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized-blind study. Blood 1996; 88: 4063–4071.

    CAS  PubMed  Google Scholar 

  10. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestation of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  PubMed  Google Scholar 

  11. Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM . Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Bone Marrow Transplantation 1989; 4: 247–254.

    CAS  PubMed  Google Scholar 

  12. Ringdén O, Labopin M, Tura S, Arcese W, Iriondo A, Zittoun R et al. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996; 93: 637–645.

    Article  PubMed  Google Scholar 

  13. Smith FO, Alonzo TA, Gerbing RB, Woods WG, Arceci RJ . Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia 2005; 19: 2054–2062.

    Article  CAS  PubMed  Google Scholar 

  14. Lange BJ, Smith FO, Feusner J, Barnard D, Dinndorf P, Feig S et al. Outcomes in CCG-2961, a Children's Oncology Group phase 3 trial for untreated pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2008; 111: 1044–1053.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J . Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood 2007; 110: 3532–3539.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are indebted to the patients, patients' families, nursing and medical staff of the 8B unit and the oncology units at our partner centers for the provision of excellent patient care, which has been crucial for the achievement of the results reported here.

Author information

Authors and Affiliations

  1. Division of Haematology/Oncology/BMT, Hospital for Sick Children, University of Toronto, Ontario, Canada

    A Gassas, S Afzal, M K Ishaqi, T Finkelstein-Shechter, M Rojas, L Sung & J Doyle

  2. Division of Clinical Research Support Unit, Hospital for Sick Children, University of Toronto, Ontario, Canada

    A Dupuis

Authors
  1. A Gassas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Afzal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M K Ishaqi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Finkelstein-Shechter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Rojas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Dupuis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L Sung
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Doyle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Gassas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gassas, A., Afzal, S., Ishaqi, M. et al. Pediatric standard-risk AML with fully matched sibling donors: to transplant in first CR or not?. Bone Marrow Transplant 42, 393–396 (2008). https://doi.org/10.1038/bmt.2008.182

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.182

Keywords

Search

Advanced search

Quick links